Ionis Pharmaceuticals
IONS
364 hedge funds and large institutions have $5.55B invested in Ionis Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 127 increasing their positions, 111 reducing their positions, and 67 closing their positions.
73% more call options, than puts
Call options by funds: $56.3M | Put options by funds: $32.5M
14% more repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 111
1.74% more ownership
Funds ownership: 85.94% → 87.67% (+1.7%)
5% less funds holding
Funds holding: 382 → 364 (-18)
18% less capital invested
Capital invested by funds: $6.8B → $5.55B (-$1.25B)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
21% less first-time investments, than exits
New positions opened: 53 | Existing positions closed: 67
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$153M |
| 2 |
Swedbank
Stockholm,
Sweden
|
+$62.5M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$55.8M |
| 4 |
ClearBridge Investments
New York
|
+$27.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$57.2M |
| 2 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$29.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$29.8M |
| 4 |
State Street
Boston,
Massachusetts
|
-$28.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$25.4M |
IONS Hedge Fund Activity: Q1 2021 in Review
364 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q1 2021, worth a combined $5.55B — down 18% from $6.8B a quarter earlier.
Sellers outnumbered buyers: 67 funds closed out of IONS and 53 opened new positions — a net loss of 14 holders — while 111 trimmed existing stakes and 127 added.
The largest buyer was ARK Investment Management, adding an estimated $153M. The largest seller was Invesco, cutting an estimated $57.2M.
- 364 institutional investors held Ionis Pharmaceuticals (IONS) as of Q1 2021, down from 382 in Q4 2020.
- Funds reported $5.55B of Ionis Pharmaceuticals stock for Q1 2021, down 18% quarter-over-quarter.
- 53 funds opened new Ionis Pharmaceuticals positions in Q1 2021 and 67 closed out, a net change of -14 holders.
- The largest Ionis Pharmaceuticals buyer in Q1 2021 was ARK Investment Management, an estimated $153M added.
- The largest Ionis Pharmaceuticals seller in Q1 2021 was Invesco, an estimated $57.2M sold.
Based on aggregated 13F filings for Q1 2021.